Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ARQT Stock Summary
Top 10 Correlated ETFs
ARQT
In the News
Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference
Arcutis today announced that Arcutis management will participate in the 23rd Annual Needham Virtual Healthcare Conference, taking place April 8-11, 2024.
Arcutis Biotherapeutics, Inc. (ARQT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Arcutis Biotherapeutics, Inc. (ARQT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Wall Street Analysts See a 54.78% Upside in Arcutis Biotherapeutics, Inc. (ARQT): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 54.8% in Arcutis Biotherapeutics, Inc. (ARQT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts See a 58.85% Upside in Arcutis Biotherapeutics, Inc. (ARQT): Can the Stock Really Move This High?
The consensus price target hints at a 58.9% upside potential for Arcutis Biotherapeutics, Inc. (ARQT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Is Arcutis Biotherapeutics (ARQT) Outperforming Other Medical Stocks This Year?
Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Athira Pharma, Inc. (ATHA) have performed compared to their sector so far this year.
Arcutis to Present at the TD Cowen 44th Annual Health Care Conference
WESTLAKE VILLAGE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in the TD Cowen 44th Annual Health Care Conference.
Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results
Arcutis today announced that it will report its fourth quarter and full year financial results and provide a business update on Tuesday, February 27, 2024.
3 Once-in-a-Lifetime Biotech Stocks With Unprecedented Surge Potential
The biotech sector is one of my favorite sectors since it is not only constantly growing and with companies that are always doing wonderful research, products, and solutions, but it is also a sector that is constantly innovating and contributing to the health of the human being. If you want to participate as an investor in this sector and take advantage of companies that have great growth opportunities, here are three biotech stocks with potential that you can consider adding to your portfolio.
Arcutis to Present at the Guggenheim Healthcare Talks – 6th Annual Biotechnology Conference
WESTLAKE VILLAGE, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in the Guggenheim Healthcare Talks – 6th Annual Biotechnology Conference.
Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture
Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture
ARQT Financial details
ARQT Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0.07 | 0.86 | |
Net income per share | -1.2 | -3.8 | -4.17 | -5.84 | -3.78 | |
Operating cash flow per share | -1.22 | -3.17 | -3.53 | -4.68 | -3.56 | |
Free cash flow per share | -1.23 | -3.18 | -3.55 | -5.11 | -3.57 | |
Cash per share | 2.89 | 7.97 | 7.83 | 7.44 | 3.94 | |
Book value per share | -1.85 | 7.59 | 6.03 | 3.81 | 1.28 | |
Tangible book value per share | -1.85 | 7.59 | 6.03 | 3.68 | 1.19 | |
Share holders equity per share | -1.85 | 7.59 | 6.03 | 3.81 | 1.28 | |
Interest debt per share | 0.01 | 0.14 | 1.57 | 3.96 | 3.35 | |
Market cap | 764.4M | 1B | 1.02B | 814.48M | 223.86M | |
Enterprise value | 701.38M | 943.23M | 1.01B | 963.38M | 340.45M | |
P/E ratio | -18.2 | -7.4 | -4.98 | -2.54 | -0.85 | |
Price to sales ratio | 0 | 0 | 0 | 220.97 | 3.76 | |
POCF ratio | -17.84 | -8.88 | -5.87 | -3.16 | -0.91 | |
PFCF ratio | -17.72 | -8.85 | -5.83 | -2.9 | -0.9 | |
P/B Ratio | -11.75 | 3.71 | 3.44 | 3.89 | 2.52 | |
PTB ratio | -11.75 | 3.71 | 3.44 | 3.89 | 2.52 | |
EV to sales | 0 | 0 | 0 | 261.36 | 5.71 | |
Enterprise value over EBITDA | -16.33 | -6.91 | -4.87 | -3.26 | -1.42 | |
EV to operating cash flow | -16.37 | -8.34 | -5.76 | -3.74 | -1.38 | |
EV to free cash flow | -16.26 | -8.32 | -5.73 | -3.43 | -1.38 | |
Earnings yield | -0.05 | -0.14 | -0.2 | -0.39 | -1.17 | |
Free cash flow yield | -0.06 | -0.11 | -0.17 | -0.35 | -1.11 | |
Debt to equity | 0 | 0.02 | 0.26 | 0.97 | 2.28 | |
Debt to assets | 0 | 0.02 | 0.19 | 0.45 | 0.59 | |
Net debt to EBITDA | 1.47 | 0.44 | 0.09 | -0.5 | -0.49 | |
Current ratio | 20.33 | 12.96 | 12.09 | 11.57 | 7.08 | |
Interest coverage | 0 | 0 | 0 | -19.27 | -8.11 | |
Income quality | 1.02 | 0.83 | 0.85 | 0.83 | 0.94 | |
Dividend Yield | 0 | 0 | 0.07 | 0.15 | 0 | |
Payout ratio | 0 | 0 | -0.35 | -0.38 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 33.13 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 49.49 | 1.86 | |
Intangibles to total assets | 0 | 0 | 0 | 0.02 | 0.02 | |
Capex to operating cash flow | 0.01 | 0 | 0.01 | 0.09 | 0 | |
Capex to revenue | 0 | 0 | 0 | -6.32 | -0.01 | |
Capex to depreciation | -1.51 | -2.63 | -2.19 | -24.93 | -0.23 | |
Stock based compensation to revenue | 0 | 0 | 0 | 8.87 | 0.65 | |
Graham number | 7.07 | 25.48 | 23.77 | 22.37 | 10.43 | |
ROIC | 0.67 | -0.49 | -0.54 | -0.75 | -0.83 | |
Return on tangible assets | -0.39 | -0.45 | -0.5 | -0.73 | -0.78 | |
Graham Net | -2.02 | 7.2 | 5.62 | 3.27 | 0.66 | |
Working capital | 101.24M | 270.22M | 369.45M | 399.6M | 283.76M | |
Tangible asset value | -65.03M | 270.62M | 297.68M | 202.39M | 82.23M | |
Net current asset value | -65.57M | 265.18M | 292.3M | 197.71M | 77.73M | |
Invested capital | 0 | 0.02 | 0.26 | 0.97 | 2.28 | |
Average receivables | 0 | 255K | 436K | 4.41M | 17.13M | |
Average payables | 1.6M | 4.27M | 7.25M | 8.09M | 10.41M | |
Average inventory | 0 | -255K | 335K | 4.35M | 10.32M | |
Days sales outstanding | 0 | 0 | 0 | 837.54 | 158.03 | |
Days payables outstanding | 2.63K | 5.73K | 3.52K | 4.27K | 715.44 | |
Days of inventory on hand | 0 | -409.12 | 564.48 | 3.64K | 783.57 | |
Receivables turnover | 0 | 0 | 0 | 0.44 | 2.31 | |
Payables turnover | 0.14 | 0.06 | 0.1 | 0.09 | 0.51 | |
Inventory turnover | 0 | -0.89 | 0.65 | 0.1 | 0.47 | |
ROE | 0.65 | -0.5 | -0.69 | -1.53 | -2.96 | |
Capex per share | -0.01 | -0.01 | -0.02 | -0.42 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.05 | 0.05 | 0.08 | 0.62 | 0.15 | |
Net income per share | -1.24 | -1.3 | -1.16 | -0.73 | -0.72 | |
Operating cash flow per share | -1.17 | -1.31 | -1.08 | -0.71 | -0.61 | |
Free cash flow per share | -1.17 | -1.31 | -1.09 | -0.71 | -0.61 | |
Cash per share | 6.72 | 5.43 | 4.37 | 3.68 | 2.95 | |
Book value per share | 3.44 | 2.28 | 1.31 | 0.76 | 0.96 | |
Tangible book value per share | 3.32 | 2.17 | 1.2 | 0.65 | 0.96 | |
Share holders equity per share | 3.44 | 2.28 | 1.31 | 0.76 | 0.96 | |
Interest debt per share | 3.44 | 3.44 | 3.44 | 3.44 | 2.27 | |
Market cap | 902.2M | 672.86M | 585.43M | 327.77M | 299.03M | |
Enterprise value | 1.05B | 794.83M | 684.54M | 425.37M | 415.63M | |
P/E ratio | -2.98 | -2.11 | -2.06 | -1.83 | -1.13 | |
Price to sales ratio | 304.69 | 241.95 | 112.8 | 8.6 | 22.11 | |
POCF ratio | -12.7 | -8.37 | -8.81 | -7.45 | -5.32 | |
PFCF ratio | -12.67 | -8.37 | -8.77 | -7.44 | -5.32 | |
P/B Ratio | 4.3 | 4.82 | 7.27 | 7.02 | 3.37 | |
PTB ratio | 4.3 | 4.82 | 7.27 | 7.02 | 3.37 | |
EV to sales | 354.98 | 285.81 | 131.9 | 11.16 | 30.73 | |
Enterprise value over EBITDA | -16.14 | -10.88 | -10.76 | -12.44 | -6.84 | |
EV to operating cash flow | -14.79 | -9.89 | -10.3 | -9.67 | -7.39 | |
EV to free cash flow | -14.77 | -9.88 | -10.25 | -9.66 | -7.39 | |
Earnings yield | -0.08 | -0.12 | -0.12 | -0.14 | -0.22 | |
Free cash flow yield | -0.08 | -0.12 | -0.11 | -0.13 | -0.19 | |
Debt to equity | 0.97 | 1.46 | 2.54 | 4.39 | 2.28 | |
Debt to assets | 0.45 | 0.54 | 0.64 | 0.7 | 0.59 | |
Net debt to EBITDA | -2.29 | -1.67 | -1.56 | -2.86 | -1.92 | |
Current ratio | 11.57 | 9.93 | 8.43 | 6.72 | 7.08 | |
Interest coverage | -9.9 | -10.83 | -9.08 | -4.88 | -7.88 | |
Income quality | 0.99 | 1 | 0.94 | 0.98 | 0.85 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 16.76 | 2.08 | 8.86 | 1.25 | 0 | |
Research and developement to revenue | 11.44 | 12.71 | 4.86 | 0.69 | 1.76 | |
Intangibles to total assets | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | -0.04 | -0.03 | -0.05 | 0 | 0 | |
Capex to depreciation | -0.35 | -0.23 | -0.72 | -0.17 | -0.02 | |
Stock based compensation to revenue | 3.13 | 3.41 | 2.04 | 0.26 | 0.65 | |
Graham number | 9.8 | 8.19 | 5.84 | 3.51 | 3.93 | |
ROIC | -0.17 | -0.22 | -0.26 | -0.15 | -0.21 | |
Return on tangible assets | -0.17 | -0.21 | -0.23 | -0.16 | -0.2 | |
Graham Net | 2.95 | 1.74 | 0.76 | 0.04 | 0.5 | |
Working capital | 399.6M | 330.65M | 272.21M | 239.66M | 283.76M | |
Tangible asset value | 202.39M | 132.73M | 73.7M | 40.09M | 82.23M | |
Net current asset value | 197.71M | 127.95M | 68.69M | 35.31M | 77.73M | |
Invested capital | 0.97 | 1.46 | 2.54 | 4.39 | 2.28 | |
Average receivables | 5.44M | 10.61M | 14.99M | 18.31M | 22.61M | |
Average payables | 8.75M | 10.66M | 14.82M | 15.17M | 12.59M | |
Average inventory | 5.91M | 8.03M | 9.51M | 12.19M | 13.52M | |
Days sales outstanding | 257.08 | 413.24 | 298.39 | 45.86 | 171.72 | |
Days payables outstanding | 1.64K | 1.44K | 1.99K | 1K | 441.6 | |
Days of inventory on hand | 1.39K | 982.87 | 1.21K | 1.06K | 483.66 | |
Receivables turnover | 0.35 | 0.22 | 0.3 | 1.96 | 0.52 | |
Payables turnover | 0.05 | 0.06 | 0.05 | 0.09 | 0.2 | |
Inventory turnover | 0.06 | 0.09 | 0.07 | 0.08 | 0.19 | |
ROE | -0.36 | -0.57 | -0.88 | -0.96 | -0.75 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
ARQT Frequently Asked Questions
What is Arcutis Biotherapeutics, Inc. stock symbol ?
Arcutis Biotherapeutics, Inc. is a US stock , located in Westlake village of Ca and trading under the symbol ARQT
Is Arcutis Biotherapeutics, Inc. buy or a sell ?
3 stock analysts have 3 predictions with a medium analyst target price of $32. The lowest prediction is $8 and the highest is $51
What is ARQT stock prediction ?
With a median analyst target price of $8, 1 stock analysts have made 1 forecasts in last 90 days. $8 is the lowest and $8 is the greatest projection.
What is Arcutis Biotherapeutics, Inc. stock quote today ?
Arcutis Biotherapeutics, Inc. stock price is $9.91 today.
Is Arcutis Biotherapeutics, Inc. stock public?
Yes, Arcutis Biotherapeutics, Inc. is a publicly traded company.